From phenotype to therapy.
NUSA Biotechnology is developing the NCoC platform, a human-relevant in-vitro system for investigating ASD-associated alterations in neuronal connectivity, quantifying structural and functional neural phenotypes, and supporting the discovery of more personalized therapeutic strategies.
A new approach to ASD therapeutic discovery.
Autism spectrum disorder encompasses diverse neurodevelopmental phenotypes, including differences in how neurons connect and communicate. NUSA is developing NCoC to investigate these connectivity-related phenotypes in human-relevant neural models and translate complex biology into quantitative measurements that can be used for therapeutic research.
The NCoC platform
Making neuronal connectivity measurable. NCoC is designed to investigate ASD-associated alterations in neuronal connectivity within engineered human brain models.
Human brain models
Human-relevant neural systems designed to reproduce key aspects of neurodevelopmental biology.
Engineered connectivity
Precisely structured microenvironments designed to control and investigate neuronal connections.
Structural phenotyping
Quantitative characterization of neuronal architecture and connectivity-related phenotypes.
Functional phenotyping
Measurement of neural activity and functional properties using complementary approaches.
Therapeutic testing
A platform designed to support evaluation of potential interventions and therapeutic responses.
Connecting human biology with measurable neural phenotypes.
Complex neurodevelopmental disorders require experimental systems that can capture both the structure and function of human neural networks. NCoC is designed to bring these dimensions together within a controlled experimental environment.
Human-relevant
Engineered human neural models for investigating neurodevelopmental phenotypes.
Connectivity-focused
A platform centered on the organization and function of neuronal connections.
Quantitative
Designed to convert complex neural phenotypes into measurable experimental endpoints.
Translational
Built with therapeutic discovery and pharmaceutical/biotechnology applications in mind.
From disease biology to therapeutic discovery.
Autism spectrum disorder
Investigate neurodevelopmental phenotypes associated with altered neuronal connectivity.
Therapeutic discovery
Evaluate potential interventions against measurable structural and functional phenotypes.
Disease mechanisms
Study how alterations in neuronal organization and connectivity relate to neural function.
Personalized therapeutics
Explore whether distinct neural phenotypes can provide measurable indicators of therapeutic response.
A platform designed for translational research.
NCoC is being developed for collaboration across the research and therapeutic-development ecosystem.
Pharmaceutical companies
Human-relevant models for preclinical therapeutic research and mechanism-of-action studies.
Biotechnology companies
Disease modeling and therapeutic-development applications.
Academic research groups
Investigation of neurodevelopmental mechanisms and neural connectivity.
Neural technology companies
Quantitative characterization of neural structure and function.
Building the next generation of human neural models.
NUSA Biotechnology is an early-stage biotechnology company developing technologies at the intersection of human brain organoids, engineered microstructures, neuronal connectivity, and functional neural measurement. Our vision is to make complex neurodevelopmental phenotypes more measurable and experimentally accessible, and to help move the field from phenotype to therapy.
Maryam Moarefian, PhD
Founder & CEO
Dr. Moarefian leads NUSA’s scientific direction and business strategy as founder and CEO. A mechanical engineer with a background in microfluidics and semiconductor fabrication, engineered neural systems, and human brain-organoid platforms, she founded NUSA to build human-relevant models that make neurodevelopmental disease measurable and treatable. She sets the company’s research priorities and partnership strategy, working with pharmaceutical, biotechnology, and academic collaborators to move ASD therapeutic discovery from phenotype to therapy.
From phenotype to therapy, together.
NUSA is building relationships with pharmaceutical and biotechnology companies, academic researchers, investors, and scientific advisors interested in advancing human-relevant models for ASD therapeutic discovery.